We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Bioreclamation and CelsisIVT Combine to Create BioreclamationIVT


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bioreclamation and CelsisIVT Combine to Create BioreclamationIVT"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Bioreclamation Group, Inc. announced it has acquired Celsis In Vitro Technologies (“CelsisIVT”), a division of Celsis International Ltd. and a provider of in vitro products for the study of drug metabolism and toxicity.  Brown Gibbons Lang & Company represented the Maryland-based CelsisIVT in the transaction. Terms of the deal were not disclosed.

The two companies will combine to become BioreclamationIVT, creating a one-stop shop offering a complete range of biological tools needed to pursue new drug discovery and development.  The combined Companies’ highly specialized products enable researchers to better understand the pharmacokinetics and metabolism of newly discovered compounds.  BioreclamationIVT’s sophisticated sourcing and exceptional quality control processes help reduce the time and cost of screening drug compounds in early-stage drug discovery and development.

Advertisement